华东医药：关于全资子公司收到药品注册证书的公告

Core Points - Huadong Medicine announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., received the drug registration certificate from the National Medical Products Administration (NMPA) for Relmapirazin Injection [2] Group 1 - The approval of Relmapirazin Injection marks a significant milestone for Huadong Medicine, enhancing its product portfolio in the pharmaceutical market [2] - The drug is identified by its research code MB-102, indicating its development stage and potential therapeutic applications [2]